Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome

Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome - An Open Label Pilot Trial

Sponsoren

Hauptsponsor: University Hospital Muenster

Mitarbeiter: Novartis

Quelle University Hospital Muenster
Kurze Zusammenfassung

Primary Sjogren's syndrome (pSS) is an autoimmune disorder characterized by keratoconjunctivitis sicca and xerostomia. In addition, various extraglandular manifestations may develop. Several immunomodulating agents have been attempted in the treatment of pSS without achieving satisfactory results. Currently, there is no approved systemic treatment for pSS.

Mycophenolic acid (MPA) is a selective inhibitor of inosine-monophosphate-dehydrogenase which leads to inhibition of the de novo pathway of nucleotide synthesis. The antiproliferative effect of MPA mainly affects activated T- and B-lymphocytes because the proliferation of these cells is critically dependent on the de novo purine synthesis compared to other eukaryotic cells. Since these lymphocytes have been suggested to play a pivotal role in the inflammation and immunopathogenesis of pSS, mycophenolate-sodium might be a promising agent in the treatment of pSS.

We perform a single-centre, open-label pilot trial with Mycophenolate sodium in pSS.

detaillierte Beschreibung

Mycophenolic acid containing compounds such as mycophenolate mofetil and enteric coated mycophenolate sodium are immunosuppressive drugs approved for the prevention of transplant rejection. Mycophenolate mofetil (MMF) is an effective treatment in systemic lupus erythematosus and other autoimmune diseases.

MMF has been used as maintenance therapy after treatment with rituximab (anti-CD20 antibody) in a pSS patient. We have reported a case of successful treatment with MMF in pSS with vasculitis.

The recent observations and the immunosuppressive effect of MPA in other autoimmune diseases led us to evaluate the efficacy and safety of MPA treatment in patients with pSS refractory to other immunosuppressive agents.

The observation period will be 6 months. At baseline, after 3, and after 6 months we examine the clinical status including glandular function tests as well as different laboratory parameters associated with pSS. In addition subjective parameters will be determined on the basis of different questionnaires.

Gesamtstatus Completed
Anfangsdatum April 2005
Fertigstellungstermin September 2007
Phase Phase 1
Studientyp Interventional
Primärer Ausgang
Messen Zeitfenster
Efficacy of mycophenolate sodium for sicca syndrome and changes in laboratory values associated with the disease Basline, week 12 and week 24
Sekundäres Ergebnis
Messen Zeitfenster
Safety of mycophenolate sodium in patients with primary Sjogren's syndrome: Clinical examination, full blood count, renal function tests, liver function tests basline, after week 4, 12, and week 24
Einschreibung 12
Bedingung
Intervention

Interventionsart: Drug

Interventionsname: Mycophenolate sodium

Beschreibung: Medical treatment is initiated with one tablet of 360 mg mycophenolate sodium orally per day for eligible patient. The dosage will be increased weekly by 360 mg up to a maximum stable dose of 1440mg daily. In patients not well tolerating the drug the dosage can be reduced to 720 mg per day.

Anderer Name: Myfortic

Teilnahmeberechtigung

Kriterien:

Inclusion Criteria:

- Diagnosis of primary Sjogren' Syndrome based on the American-European Consensus criteria

- Erythrocyte sedimentation rate >25mm/h and hypergammaglobulinemia (>1500 mg/dl)

- Presence of anti-SS-A and /or SS-B antibodies and / or rheumatoid factor

- Requirement of artificial teardrops due to symptomatic sicca syndrome

- Inadequate response or intolerance of prior treatment with hydroxychloroquine and / or azathioprine

- Adequate contraception for females of childbearing potential

Exclusion Criteria:

- Age below 18 or above 75 years

- Secondary Sjogren's syndrome

- History of cancer, severe infections or other uncontrolled diseases

- Treatment with concomitant disease modifying anti-rheumatic drugs within the least 8 weeks before baseline evaluation

- Prednisolone dose of > 5mg/d or changes of prednisolone dose within the least 4 weeks before baseline

- Use of secretagogues (e.g. pilocarpine, cevimeline) or medications that potentially diminish exocrine gland function (e.g. tricyclic antidepressants, anti-cholinergic drugs)

- Pregnant or lactating women

Geschlecht: All

Mindestalter: 18 Years

Maximales Alter: 75 Years

Gesunde Freiwillige: No

Insgesamt offiziell
Nachname Rolle Zugehörigkeit
Markus Gaubitz, MD Principal Investigator University Hospital Muenster
Ort
Einrichtung: University Hospital Muenster
Standort Länder

Germany

Überprüfungsdatum

August 2004

Schlüsselwörter
Hat den Zugriff erweitert No
Bedingung Durchsuchen
Studiendesign Info

Zuweisung: N/A

Interventionsmodell: Single Group Assignment

Hauptzweck: Treatment

Maskierung: None (Open Label)

Quelle: ClinicalTrials.gov